Purified Dendritic Cell-Tumor Fusion Hybrids Supplemented with Non-Adherent Dendritic Cells Fraction Are Superior Activators of Antitumor Immunity

BACKGROUND: Strong evidence supports the DC-tumor fusion hybrid vaccination strategy, but the best fusion product components to use remains controversial. Fusion products contain DC-tumor fusion hybrids, unfused DCs and unfused tumor cells. Various fractions have been used in previous studies, inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yunfei, Luo, Wen, Wang, Yucai, Liu, Yunyan, Zheng, Lianhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900640/
https://www.ncbi.nlm.nih.gov/pubmed/24466232
http://dx.doi.org/10.1371/journal.pone.0086772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900640/
https://www.ncbi.nlm.nih.gov/pubmed/24466232
http://dx.doi.org/10.1371/journal.pone.0086772

Ejemplares similares